Claims for Patent: 7,083,808

Summary for Patent: 7,083,808

Title:	Controlled/modified release oral methylphenidate formulations
Abstract:	The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.
Inventor(s):	Goldenheim; Paul D. (Wilton, CT), Sackler; Richard S. (Greenwich, CT), Krishnamurthy; Thinnayam N. (Ontario, CA), Darke; Andrew (Ontario, CA), Oshlaci; Benjamin (New York, NY)
Assignee:	Euro-Celtique S.A. (Luxembourg, LU)
Application Number:	10/741,081
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,083,808
Patent Claims:	1. An oral dosage form comprising an effective amount of methylphenidate or a pharmaceutically acceptable salt thereof, wherein a portion of the methylphenidate or pharmaceutically acceptable salt thereof is in immediate release form and a portion of the methylphenidate or pharmaceutically acceptable salt thereof is in controlled release form, the controlled release form comprising a substrate comprising about 60% to about 70% of the methylphenidate or a pharmaceutically acceptable salt thereof and at least one pH dependent release modifying coating, wherein the pH dependent release modifying coating is applied to obtain a weight gain from about 2 to about 25% of the substrate, the formulation providing a time to maximum plasma concentration at about 0.5 to about 4 hours after oral administration, a peak plasma concentration from about 3 ng/ml to about 6.5 ng/ml per 20 mg dose of methylphenidate contained in the oral dosage form, wherein the peak concentration is from about 1.0 to about 2.0 times the plasma concentration of methylphenidate provided by the formulation at about 9 hours after oral administration, wherein the formulation provides an in-vitro dissolution as follows: TABLE-US-00043 Time % Methylphenidate (hours) HCl dissolved 0.25 0 45% 1 5 50% 4 40 90% 8 NLT 60% 12 NLT 80% and wherein the duration of effect provided by the methylphenidate contained in the formulation falls below effective plasma concentrations at about 8 to about 12 hours after oral administration, wherein about 30% to about 40% of the methylphenidate or pharmaceutically acceptable salt thereof is in immediate release form. 2. The oral dosage form of claim 1, wherein the oral dosage form provides a time to maximum plasma concentration at about 0.5 to about 2 hours after oral administration. 3. The oral dosage form of claim 2, wherein the peak plasma concentration is from about 1.0 to about 1.7 times the plasma concentration of methylphenidate provided by the formulation at about 9 hours after oral administration. 4. The oral dosage form of claim 3, wherein the duration of effect provided by the methylphenidate contained in the oral dosage form falls below effective plasma concentrations at about 8 to about 10 hours after oral administration. 5. The oral dosage form of claim 1, which provides a "square wave" plasma profile as depicted by Formulation 1. 6. The oral dosage form of claim 1, which provides an in-vitro dissolution as follows: TABLE-US-00044 Time % Methylphenidate (hours) HCl dissolved 0.25 0 45% 1 10 50% 4 30 80% 8 NLT 65% 12 NLT 80% 7. The oral dosage form of claim 1, wherein the pH dependent release modifying coating is selected from the group consisting of shellac, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate, a pH dependent methacrylic acid ester copolymer and zein. 8. The oral dosage form of claim 7, wherein the pH dependent coating is a pH dependent methacrylic acid ester copolymer. 9. The oral dosage form of claim 1, wherein the substrate comprises methylphenidate or pharmaceutically acceptable salt thereof coated onto inert beads. 10. The oral dosage form of claim 9, wherein the coated inert beads are overcoated with at least a portion of the pH dependent release modifying coating.